AJL Ophthalmic
Financials
Estimates*
EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|
Revenues | 10.5m | 11.9m | 12.4m | 11.5m | 13.4m | 14.7m | 18.5m |
% growth | 8 % | 13 % | 4 % | (7 %) | 17 % | 10 % | 26 % |
EBITDA | 2.2m | 3.2m | 3.0m | 3.2m | 3.6m | 3.4m | - |
% EBITDA margin | 21 % | 27 % | 24 % | 28 % | 27 % | 23 % | - |
Profit | <1m | 1.6m | 1.5m | 1.8m | 2.0m | 1.8m | - |
% profit margin | 5 % | 13 % | 12 % | 15 % | 15 % | 12 % | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
€30.0k | Grant | ||
Total Funding | €30.0k |
Recent News about AJL Ophthalmic
EditAJL Ophthalmic S.A. specializes in the design, manufacture, and distribution of advanced ophthalmic medical devices. The company serves ophthalmologists and eye care professionals globally, providing innovative solutions for vision correction and eye health. AJL operates in the medical device market, focusing on products such as intraocular lenses, corneal rings, and crosslinking systems. The business model is based on the development and sale of high-quality ophthalmic products, generating revenue through direct sales and partnerships with healthcare providers. Key clients include hospitals, clinics, and specialized eye care centers. AJL's commitment to research and development ensures a continuous pipeline of cutting-edge products that meet the evolving needs of the ophthalmic community.
Keywords: ophthalmic, intraocular lenses, corneal rings, crosslinking systems, vision correction, eye health, medical devices, innovation, healthcare, research and development.